Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | CHUK | O15111 | 3/20 | 0.41 |
| ▸ | IKBKB | O14920 | 2/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | MELK | Q14680 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | BUB1 | O43683 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.37 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16102737 | 0.94 | KDM4C (0.46) | CHRNB4CHRNA3CHUKIKBKBCHRNB2 | |
| SCHEMBL16119894 | 0.92 | SCN9A (0.41) | CHRNB4CHRNA3CHUKIKBKBGSK3A | |
| SCHEMBL16094215 | 0.89 | PDE4D (0.41) | CHRNB4CHRNA3CHUKIKBKBGSK3A | |
| SCHEMBL16102686 | 0.88 | SCN9A (0.36) | CHRNB4CHRNA3CHUKIKBKBGSK3A | |
| SCHEMBL16102685 | 0.88 | SCN9A (0.36) | CHRNB4CHRNA3CHUKIKBKBGSK3A | |
| SCHEMBL15716810 | 0.88 | CHRNB4 (0.43) | CHRNB4CHRNA3CHUKIKBKBGSK3A | |
| SCHEMBL16094368 | 0.86 | CHUK (0.34) | CHRNB4CHRNA3CHUKIKBKBGSK3A | |
| SCHEMBL24456599 | 0.84 | ROCK2 (0.44) | CHRNB4CHRNA3MELKCHRNB2CHRNA4 | |
| SCHEMBL4069716 | 0.79 | CHRNB4 (0.41) | CHRNB4CHRNA3CHUKIKBKBGSK3A | |
| SCHEMBL15784059 | 0.79 | CHRNB4 (0.41) | CHRNB4CHRNA3CHUKIKBKBGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190248803-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-15 | — | — | US | disclosed |
| US-20190248803-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-15 | — | — | US | disclosed |
| US-10308659-B2 | Pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10308659-B2 | Pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-06-04 | — | — | US | disclosed |
| CN-105121436-B | New pyridine derivate | 豪夫迈·罗氏有限公司 | 2018-07-27 | — | — | CN | disclosed |
| EP-2978755-B1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-01-03 | — | — | EP | disclosed |
| EP-2928867-B1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2017-08-09 | — | — | EP | disclosed |
| EP-2928867-B1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2017-08-09 | — | — | EP | disclosed |
| CN-104837818-B | It can be used as the acid amides of pyridine 2 of CB2 activators | 霍夫曼-拉罗奇有限公司 | 2017-07-14 | — | — | CN | disclosed |
| EP-2598481-B1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-31 | — | — | EP | disclosed |
| WO-2014154612-A1 | NOVEL PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014154612-A1 | NOVEL PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014086805-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014086805-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-29 | — | — | US | disclosed |
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-29 | — | — | US | disclosed |
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-29 | — | — | US | disclosed |
| EP-2598481-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015723-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012015723-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | SULT1A1, SULT2A1, SULT1E1 | CHRNB4 4077/4885CHRNA3 3421/4885CHUK 285/4885 |
| US-10308659-B2 | Pyridine derivatives | NDUFS6, NDUFS4, NDUFS8 | CHRNB4 1416/4885CHRNA3 1298/4885CHUK 1398/4885 |
| US-20190248803-A1 | NOVEL PYRIDINE DERIVATIVES | NDUFS6, NDUFS4, NDUFV1 | CHRNB4 841/4885CHRNA3 820/4885CHUK 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.